Gilead part­ner Ar­cus earns an­a­lyst­s' plau­dits for ear­ly pan­cre­at­ic can­cer da­ta that 'ex­ceed­ed ex­pec­ta­tion­s'

Ar­cus’ small mol­e­cule CD73 in­hibitor for pan­cre­at­ic can­cer got a stand­ing ova­tion from an­a­lysts who said pre­lim­i­nary da­ta “ex­ceed­ed ex­pec­ta­tions”— mak­ing waves in a field …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER